Pfizer Stops Swinging For The Fences; Combo Products Are Big Opportunity

Pfizer is investing more heavily in low-risk "product enhancements" to help round out its R&D portfolio

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet